A11HA02 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎 | 1 |
93. 原発性胆汁性胆管炎
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-006742-34-GB (EUCTR) | 20/12/2007 | 03/06/2007 | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | primary biliary cirrhosis MedDRA version: 9.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis | Trade Name: Ezetrol Product Name: Ezetimibe Product Code: EZT INN or Proposed INN: EZETIMIBE Trade Name: pyridoxine 10mg BP Product Name: pyridoxine 10mg Product Code: A11HA02 INN or Proposed INN: PYRIDOXINE | Barts and The London NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |